Early clinical experience with a degraded 4 MeV electron beam in radiotherapy of superficial basal cell carcinoma

Autor: Assi Valve, Sari Koskenmies, Mikko Tenhunen, Heidi Nurmi, Micaela Hernberg, Samuli Salminen, Anu Anttonen

Publikováno v: Physics and Imaging in Radiation Oncology, Vol 27, Iss , Pp 100487- (2023)

The most common non-melanoma skin cancer is basal cell carcinoma (BCC). Surgery is the gold standard treatment but also non-surgical alternatives are needed. The purpose of this work was to present the early clinical experiences of degraded 4 MeV ele

Externí odkaz: https://doaj.org/article/b9812af9b2694127932108eb1f00cfe9

The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP

Autor: Silvia Uccella, Ritsuko Seki, Diana O. Treaba, Jorge J. Castillo, Jun-Min Li, Brady E Beltran, Moo-Kon Song, Ivana Ilić, Dariusz Stachurski, Heidi Nurmi, Sirpa Leppä, James N. Butera

Publikováno v: Leukemia Research. 36:413-417

Our objective was to evaluate the non-germinal center (GC) profile as a marker for response and survival in DLBCL and to compare the characteristics of patients with GC and non-GC DLBCL treated with rituximab-containing regimens. In this patient-leve

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc0d27dba25a3744934dfeb46ec9a0fb
https://doi.org/10.1016/j.leukres.2011.12.012

High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy

Autor: Karin Rydström, Heidi Nurmi, Sari Riihijärvi, Sirpa Leppä, Magnus Björkholm, Mikael Eriksson, Harald Holte, Lars Moller Pedersen, Øystein Fluge, Mats Jerkeman

Publikováno v: Riihijärvi, S, Nurmi, H, Holte, H, Björkholm, M, Fluge, O, Pedersen, L M, Rydström, K, Jerkeman, M, Eriksson, M & Leppä, S 2012, ' High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy ', European Journal of Haematology, vol. 89, no. 5, pp. 395-402 . https://doi.org/10.1111/ejh.12005

Objectives To determine whether serum vascular endothelial growth factor (s-VEGF) levels and VEGF gene expression in tumor tissue predict survival of diffuse large B-cell lymphoma (DLBCL) patients treated with chemoimmunotherapy. Methods VEGF levels

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eb3fc7eb3b10e92606d1517d19c4098
https://portal.findresearcher.sdu.dk/da/publications/b4ac2d43-7601-4f08-a01b-8d0704884ded